Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total value of $498,700.00. Following the completion of the sale, the insider now directly owns 95,648 shares of the company’s stock, valued at approximately $4,769,965.76. This represents a 9.47 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Catriona Yale also recently made the following trade(s):

• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The shares were sold at an average price of $29.11, for a total value of $264,144.14.

Akero Therapeutics Price Performance

AKRO stock opened at $51.84 on Monday. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $37.02 and a two-hundred day moving average of $31.79. The stock has a market cap of $3.62 billion, a price-to-earnings ratio of -13.82 and a beta of -0.11.

Institutional Investors Weigh In On Akero Therapeutics

A number of institutional investors have recently modified their holdings of AKRO. Wellington Management Group LLP grew its stake in shares of Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after buying an additional 2,782,029 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Akero Therapeutics in the third quarter valued at $37,392,000. RTW Investments LP grew its stake in shares of Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock valued at $190,840,000 after buying an additional 940,388 shares in the last quarter. Deep Track Capital LP grew its stake in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock valued at $41,452,000 after buying an additional 800,216 shares in the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at $18,059,000.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Morgan Stanley increased their price target on Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. UBS Group increased their price target on Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. HC Wainwright increased their price target on Akero Therapeutics from $50.00 to $72.00 and gave the company a “buy” rating in a report on Monday, January 27th. Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $35.00 to $63.00 in a research note on Thursday, January 30th. Finally, Canaccord Genuity Group raised their target price on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $75.86.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.